Overview

An Efficacy and Safety Study of Ravulizumab in ALS Participants

Status:
Active, not recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the efficacy and safety of ravulizumab for the treatment of adult participants with ALS.
Phase:
Phase 3
Details
Lead Sponsor:
Alexion Pharmaceuticals
Treatments:
Ravulizumab